Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors | Clinical Trial - ANNEXA-A


One of the biggest drawbacks with novel oral anticoagulants (NOACs) such as rivaroxaban and apixaban is the availability of a reliable antidote in emergent situations, such as significant bleeding. The current trial sought to compare the safety and efficacy of andexanet alfa in reversing the anticoagulant effect of apixaban.